Altimmune
ALT
29 hedge funds and large institutions have $4.18M invested in Altimmune in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.07% less ownership
Funds ownership: 0.46% → 0.39% (-0.07%)
29% less funds holding
Funds holding: 41 → 29 (-12)
39% less capital invested
Capital invested by funds: $6.83M → $4.18M (-$2.65M)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
71% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$77.9K |
| 2 |
Squarepoint
New York
|
+$52.9K |
| 3 |
SEI Investments
Oaks,
Pennsylvania
|
+$23.5K |
| 4 |
JIR
James Investment Research
Alpha,
Ohio
|
+$19.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$187K |
| 2 |
ECM
Element Capital Management
New York
|
-$151K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$112K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$93.7K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$77K |
ALT Hedge Fund Activity: Q3 2017 in Review
29 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2017, worth a combined $4.18M — down 39% from $6.83M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ALT and 5 opened new positions — a net loss of 12 holders — while 11 trimmed existing stakes and 4 added.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $77.9K. The largest seller was Goldman Sachs, exiting entirely with an estimated $187K sold.
- 29 institutional investors held Altimmune (ALT) as of Q3 2017, down from 41 in Q2 2017.
- Funds reported $4.18M of Altimmune stock for Q3 2017, down 39% quarter-over-quarter.
- 5 funds opened new Altimmune positions in Q3 2017 and 17 closed out, a net change of -12 holders.
- The largest Altimmune buyer in Q3 2017 was JP Morgan Chase, an estimated $77.9K added.
- The largest Altimmune seller in Q3 2017 was Goldman Sachs, an estimated $187K sold.
Based on aggregated 13F filings for Q3 2017.